A bio-assay for effectors of osteoclast differentiation in serum from patients with bone disease

Hdl Handle:
http://hdl.handle.net/10034/67764
Title:
A bio-assay for effectors of osteoclast differentiation in serum from patients with bone disease
Authors:
Dugard, Marit-Naomi; Sharp, Christopher A.; Evans, Sally F.; Williams, John H. H.; Davie, Michael W. J.; Marshall, Michael J.
Abstract:
Osteoclast differentiation and activity, and hence bone loss, depend on two opposing cytokines. Receptor activator of NF-κB ligand (RANKL) produced by osteoblasts and T-cells stimulates, while osteoprotegerin inhibits. Both of these cytokines are found in serum. Our aim was to develop a functional assay for any factors present in human serum that can affect osteoclast differentiation and to assess whether any such factors vary in diseases in which bone loss occurs.
Affiliation:
Charles Salt Centre, Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Trust in Oswestry ; Charles Salt Centre, Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Trust in Oswestry ; Charles Salt Centre, Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Trust in Oswestry ; University of Chester ; Charles Salt Centre, Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Trust in Oswestry ; Charles Salt Centre, Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Trust in Oswestry
Citation:
Clinica Chimica Acta, 356(1-2), (2005), pp. 154-163.
Publisher:
Elsevier
Journal:
Clinica Chimica Acta
Publication Date:
Jun-2005
URI:
http://hdl.handle.net/10034/67764
DOI:
10.1016/j.cccn.2005.01.020
Additional Links:
http://www.elsevier.com/wps/find/journaldescription.cws_home/506018/description#description
Type:
Article
Language:
en
Description:
This article is not available through ChesterRep.
ISSN:
0009-8981
Appears in Collections:
Biological Sciences

Full metadata record

DC FieldValue Language
dc.contributor.authorDugard, Marit-Naomien
dc.contributor.authorSharp, Christopher A.en
dc.contributor.authorEvans, Sally F.en
dc.contributor.authorWilliams, John H. H.en
dc.contributor.authorDavie, Michael W. J.en
dc.contributor.authorMarshall, Michael J.en
dc.date.accessioned2009-05-11T11:45:16Zen
dc.date.available2009-05-11T11:45:16Zen
dc.date.issued2005-06en
dc.identifier.citationClinica Chimica Acta, 356(1-2), (2005), pp. 154-163.en
dc.identifier.issn0009-8981en
dc.identifier.doi10.1016/j.cccn.2005.01.020en
dc.identifier.urihttp://hdl.handle.net/10034/67764en
dc.descriptionThis article is not available through ChesterRep.en
dc.description.abstractOsteoclast differentiation and activity, and hence bone loss, depend on two opposing cytokines. Receptor activator of NF-κB ligand (RANKL) produced by osteoblasts and T-cells stimulates, while osteoprotegerin inhibits. Both of these cytokines are found in serum. Our aim was to develop a functional assay for any factors present in human serum that can affect osteoclast differentiation and to assess whether any such factors vary in diseases in which bone loss occurs.en
dc.language.isoenen
dc.publisherElsevieren
dc.relation.urlhttp://www.elsevier.com/wps/find/journaldescription.cws_home/506018/description#descriptionen
dc.subjectosteoclasten
dc.subjectdifferentiationen
dc.subjectserumen
dc.subjectbone diseaseen
dc.titleA bio-assay for effectors of osteoclast differentiation in serum from patients with bone diseaseen
dc.typeArticleen
dc.contributor.departmentCharles Salt Centre, Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Trust in Oswestry ; Charles Salt Centre, Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Trust in Oswestry ; Charles Salt Centre, Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Trust in Oswestry ; University of Chester ; Charles Salt Centre, Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Trust in Oswestry ; Charles Salt Centre, Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Trust in Oswestryen
dc.identifier.journalClinica Chimica Actaen
All Items in ChesterRep are protected by copyright, with all rights reserved, unless otherwise indicated.